KIDNEY TRANSPLANTATION

This study looks at how well the shingles vaccine (Shingrix) works in adults with kidney failure who are waiting for a kidney transplant. Researchers want to see if giving an extra dose after the transplant boosts the immune response. About 132 participants will be followed for u…

This study tests whether a stomach acid drug called vonoprazan fumarate can prevent delayed graft function (DGF) in people receiving a kidney transplant from a deceased donor. DGF is when the new kidney doesn't start working right away, often requiring dialysis. The drug is given…

This study tests a new drug called ALXN2030 in 45 adults who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR). The goal is to see if the drug can help resolve signs of rejection seen on a kidney biopsy after one year of treatment. Participants w…

This study tests whether dipyridamole, a drug used for heart conditions, can raise phosphate levels in kidney transplant patients who develop low phosphate (hypophosphatemia). About 90 adult kidney transplant recipients will receive dipyridamole or a placebo. The goal is to see i…

This study tests a genetically modified pig kidney (called the 10 GE Xenokidney) in 50 adults with end-stage kidney disease who cannot get a human kidney transplant or face a long wait. The goal is to see if the pig kidney works safely and well, improving survival and quality of …

This study tests whether a specially modified pig kidney can safely work in people with end-stage kidney disease who cannot get a human kidney transplant. Up to 50 participants will receive the pig kidney and be followed for life. The goal is to see if the pig kidney can keep pat…

This study tests a new approach for people with end-stage kidney disease who have very high levels of antibodies, making it nearly impossible to find a compatible donor kidney. The treatment uses a strong medication regimen to wipe out the patient's existing immune cells, then re…

This study tests whether monitoring levels of a harmless virus called TTV can help doctors personalize immune-suppressing drugs for kidney transplant patients. The goal is to prevent long-term complications like infections, cancer, and organ rejection. About 600 adults who receiv…

This study looks at whether older kidney transplant patients (55+) can safely stop taking one of their anti-rejection drugs (mycophenolate mofetil) while still protecting their new kidney. About 350 participants will either stop the drug or continue standard care, and researchers…

This study tests whether a single infusion of specially grown immune cells (TRK-001) can help kidney transplant recipients safely reduce their lifelong anti-rejection medications. About 34 adults receiving a kidney from a living donor will either get standard care or standard car…

This early-phase trial tests whether infusing a patient's own specially-grown immune cells (called CD8+ regulatory T cells) can safely reduce the need for lifelong anti-rejection drugs after a kidney transplant. Nine living-donor kidney recipients will receive increasing doses of…

This study looks at whether a 12-week home-based exercise program is safe and helpful for adults aged 60 and older who are waiting for a kidney transplant. Participants will either receive usual care plus a fitness tracker, or usual care plus online exercise classes. The goal is …

This study tests a 6-week online program that teaches people with chronic conditions like cancer or after a kidney transplant how to better manage their health. Participants learn practical skills such as setting goals, communicating with doctors, and coping with symptoms. The go…

This study tests whether a treatment called extracorporeal phototherapy (ECP) can help kidney transplant patients whose bodies are slowly rejecting the new kidney. ECP involves taking some of the patient's blood cells, treating them with ultraviolet light, and returning them to t…